Concepedia

Mark S. Roh

MS

76

Publications

5.8K

Citations

31

H-Index

1985

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Agricultural Research Service

Allegheny General Hospital

NSABP Foundation

U.S. National Arboretum

Mark S. Roh is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and surgical oncology.

ORCID

Top concepts

Publications per year

1985–2018

76

Publications

76

Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

Mark S. Roh, Linda H. Colangelo, Michael J. O’Connell et al. · Journal of Clinical Oncology · 2009 · 935 citations · Full text

Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04

Michael J. O’Connell, Linda H. Colangelo, Robert W. Beart et al. · Journal of Clinical Oncology · 2014 · 438 citations · Full text

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.

Mark S. Talamonti, Mark S. Roh, S. Curley et al. · Journal of Clinical Investigation · 1993 · 397 citations · Full text

, , +18

Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies

A. Scott Pearson, Francesco Izzo, R.Y.Declan Fleming et al. · The American Journal of Surgery · 1999 · 370 citations

, , +6

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

Carmen J. Allegra, Greg Yothers, Michael J. O’Connell et al. · JNCI Journal of the National Cancer Institute · 2015 · 326 citations · Full text

Rows per page

1–5 of 76